

Resource Summary Report

Generated by [PRECISE-TBI](#) on Jul 31, 2026

Tg(Mx1-cre)1Cgn; Tg(JAK2*V617F)FF1Rsko

RRID:MGI:5553472

Type: Organism

Proper Citation

RRID:MGI:5553472

Organism Information

URL:

Proper Citation: RRID:MGI:5553472

Description: Allele Detail: Transgenic This is a legacy resource.

Species: Mus musculus

Notes: Allele Detail: Transgenic This is a legacy resource.

Phenotype: decreased T cell number, decreased B cell number, abnormal spleen morphology, thrombocytosis, increased hemoglobin content, increased megakaryocyte cell number, increased neutrophil cell number, increased bone marrow cell number, abnormal erythropoiesis, spleen fibrosis, myelofibrosis, increased erythrocyte cell number, increased erythroid progenitor cell number, enlarged spleen, extramedullary hematopoiesis, abnormal myelopoiesis, abnormal megakaryocyte progenitor cell morphology, decreased mean corpuscular volume

Affected Gene: Tg(JAK2*V617F)FF1Rsko, Tg(Mx1-cre)1Cgn

Genomic Alteration: Tg(JAK2*V617F)FF1Rsko, Tg(Mx1-cre)1Cgn

Catalog Number: 5553472

Background: involves: C57BL/6 * CBA

Database: MGI, Mouse Genome Informatics MGI

Database Abbreviation: MGI

Availability: Availability unknown check source stock center

Source References: [PMID:18160670](#)

Organism Name: Tg(Mx1-cre)1Cgn; Tg(JAK2*V617F)FF1Rsko

Record Creation Time: 20240120T190054+0000

Record Last Update: 20240130T201710+0000

Ratings and Alerts

No rating or validation information has been found for Tg(Mx1-cre)1Cgn; Tg(JAK2*V617F)FF1Rsko.

No alerts have been found for Tg(Mx1-cre)1Cgn; Tg(JAK2*V617F)FF1Rsko.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: MGI, Mouse Genome Informatics MGI

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Basu T, et al. (2021) Pharmacological Inhibition of Insulin Growth Factor-1 Receptor (IGF-1R) Alone or in Combination With Ruxolitinib Shows Therapeutic Efficacy in Preclinical Myeloproliferative Neoplasm Models. HemaSphere, 5(5), e565.

Brkic S, et al. (2021) Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy. Leukemia, 35(10), 2875.